Fortrea HoldingsFTRE
About: Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Employees: 14,500
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
237% more call options, than puts
Call options by funds: $6.31M | Put options by funds: $1.87M
13% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 93
5.31% more ownership
Funds ownership: 104.35% [Q1] → 109.66% (+5.31%) [Q2]
8% less funds holding
Funds holding: 357 [Q1] → 330 (-27) [Q2]
26% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 82
31% less capital invested
Capital invested by funds: $711M [Q1] → $490M (-$221M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Evercore ISI Group Elizabeth Anderson | 21%downside $7 | In-Line Maintained | 8 Aug 2025 |
Barclays Luke Sergott | 32%downside $6 | Underweight Maintained | 7 Aug 2025 |
Baird Eric Coldwell | 2%upside $9 | Outperform Upgraded | 4 Aug 2025 |
Mizuho Ann Hynes | 21%downside $7 | Neutral Maintained | 11 Jul 2025 |
Financial journalist opinion
Based on 39 articles about FTRE published over the past 30 days









